bluebird bio, Inc. (NASDAQ:BLUE) – Equities research analysts at Jefferies Group lifted their FY2019 earnings estimates for bluebird bio in a research note issued on Monday. Jefferies Group analyst B. Amin now expects that the biotechnology company will earn ($6.25) per share for the year, up from their previous estimate of ($7.01). Jefferies Group currently has a “Buy” rating and a $211.00 price target on the stock. Jefferies Group also issued estimates for bluebird bio’s FY2020 earnings at ($2.59) EPS and FY2021 earnings at $7.29 EPS.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the prior year, the firm earned ($2.07) EPS. The business’s revenue was up 397.4% on a year-over-year basis.

Other analysts have also issued reports about the company. Maxim Group reissued a “buy” rating and set a $170.00 price target (up from $100.00) on shares of bluebird bio in a research note on Monday, October 9th. BMO Capital Markets lifted their price objective on bluebird bio from $134.00 to $162.00 and gave the stock a “buy” rating in a research note on Monday, October 30th. Goldman Sachs Group reaffirmed a “buy” rating and issued a $186.00 price objective on shares of bluebird bio in a research note on Friday, October 6th. BTIG Research raised bluebird bio from a “neutral” rating to a “buy” rating and set a $177.00 price objective on the stock in a research note on Thursday, November 2nd. Finally, SunTrust Banks lifted their price objective on bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a research note on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have given a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $157.45.

bluebird bio (BLUE) traded down $6.05 during trading on Wednesday, reaching $184.90. The company’s stock had a trading volume of 4,050,794 shares, compared to its average volume of 862,906. bluebird bio has a 1 year low of $60.95 and a 1 year high of $222.03.

In related news, Director John Maraganore sold 18,868 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the completion of the sale, the director now owns 24,711 shares in the company, valued at $3,242,330.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey T. Walsh sold 35,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $151.38, for a total value of $5,298,300.00. Following the sale, the insider now owns 62,305 shares of the company’s stock, valued at approximately $9,431,730.90. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,450 shares of company stock valued at $18,073,602. Corporate insiders own 3.90% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. Ladenburg Thalmann Financial Services Inc. boosted its position in bluebird bio by 454.2% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 992 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 813 shares during the last quarter. QS Investors LLC boosted its position in bluebird bio by 70.7% in the second quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after purchasing an additional 500 shares during the last quarter. Biondo Investment Advisors LLC purchased a new position in bluebird bio in the third quarter worth $203,000. World Asset Management Inc purchased a new position in bluebird bio in the third quarter worth $230,000. Finally, Bank of Montreal Can boosted its position in bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 911 shares during the last quarter.

TRADEMARK VIOLATION NOTICE: “FY2019 EPS Estimates for bluebird bio, Inc. (BLUE) Increased by Analyst” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/13/fy2019-eps-estimates-for-bluebird-bio-inc-blue-increased-by-analyst.html.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.